CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis

Nathan Ford,[1] Zara Shubber,[2] Joseph N. Jarvis,[3,4,5] Tom Chiller,[6] Greg Greene,[6] Chantal Migone,[1] Marco Vitoria,[1] Meg Doherty,[1] and Graeme Meintjes[7,8]

[1]HIV Department, World Health Organization, Geneva, Switzerland; [2]Department of Infectious Disease Epidemiology, Imperial College London, United Kingdom; [3]Botswana-UPenn Partnership, and [4]Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; [5]Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, United Kingdom; [6]Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia; and [7]Wellcome Trust Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, and [8]Department of Medicine, Faculty of Health Sciences, University of Cape Town, South Africa

Background. Current guidelines recommend screening all people living with human immunodeficiency virus (PLHIV) who have a CD4 count ≤100 cells/µL for cryptococcal antigen (CrAg) to identify those patients who could benefit from preemptive fluconazole treatment prior to the onset of meningitis. We conducted a systematic review to assess the prevalence of CrAg positivity at different CD4 cell counts.

Methods. We searched 4 databases and abstracts from 3 conferences up to 1 September 2017 for studies reporting prevalence of CrAg positivity according to CD4 cell count strata. Prevalence estimates were pooled using random effects models.

Results. Sixty studies met our inclusion criteria. The pooled prevalence of cryptococcal antigenemia was 6.5% (95% confidence interval [CI], 5.7%–7.3%; 54 studies) among patients with CD4 count ≤100 cells/µL and 2.0% (95% CI, 1.2%–2.7%; 21 studies) among patients with CD4 count 101–200 cells/µL. Twenty-one studies provided sufficient information to compare CrAg prevalence per strata; overall, 18.6% (95% CI, 15.4%–22.2%) of the CrAg-positive cases identified at ≤200 cells/µL (n = 11 823) were identified among individuals with a CD4 count 101–200 cells/µL. CrAg prevalence was higher among inpatients (9.8% [95% CI, 4.0%–15.5%]) compared with outpatients (6.3% [95% CI, 5.3%–7.4%]).

Conclusions. The findings of this review support current recommendations to screen all PLHIV who have a CD4 count ≤100 cells/µL for CrAg and suggest that screening may be considered at CD4 cell count ≤200 cells/µL.

Keywords. advanced HIV disease; CrAg; cryptococcal antigen; cryptococcal meningitis; HIV.

The burden of cryptococcal meningitis among people living with human immunodeficiency virus (PLHIV) remains substantial despite scale-up of antiretroviral therapy (ART) [1]. A recent review estimated that globally there were 223 100 incident cryptococcal meningitis cases (with 73% of the cases occurring in sub-Saharan Africa), resulting in almost 200 000 deaths in 2014 [2].

Current World Health Organization (WHO) guidelines recommend screening all PLHIV who have a CD4 count ≤100 cells/µL for cryptococcal antigen (CrAg) to identify those patients with cryptococcal disease who could benefit from preemptive fluconazole treatment prior to the onset of meningitis. CrAg may be detected several weeks before clinical features of cryptococcal meningitis become apparent [3]. Providing preemptive fluconazole treatment during this period of antigenemia prior to onset of meningitis symptoms has been found to be life saving and cost effective across a range of settings [4–7]. Some countries have chosen higher CD4 cell count thresholds for their cryptococcal screening guidelines: Ethiopia has adopted a cutoff of 150 cells/µL, whereas in Rwanda CrAg screening is done at a CD4 count of ≤200 cells/µL.

Recent WHO guidelines advise that a CD4 threshold of ≤200 cells/µL be used to define patients who have advanced HIV disease [8], and studies have suggested there may be benefit to CrAg screening among PLHIV using a higher CD4 count threshold of ≤200 cells/µL to identify additional numbers of PLHIV at risk of developing cryptococcal meningitis [9–12]. The current recommended threshold for CrAg screening at CD4 count ≤100 cells/µL is based on evidence from a limited number of studies, and there may be benefits to simplifying screening strategies to target all patients with advanced human immunodeficiency virus (HIV) disease. We conducted a systematic review to assess prevalence of CrAg positivity at CD4 count ≤100 cells/µL compared to 101–200 cells/µL across a range of settings.

METHODS

Search Strategy and Selection Criteria

This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [13]. Using a study protocol (available from the corresponding author), we sought randomized and quasi-randomized controlled trials, and comparative and noncomparative observational studies reporting prevalence of CrAg positivity according to CD4 cell count strata.

Using a broad search strategy combining terms for HIV infection and CrAg screening, 3 investigators (N. F., Z. S., C. M.), working independently and in duplicate, screened titles and abstracts from Medline via PubMed, Embase, and the Cochrane library, from inception to 1 September 2017. Abstracts from the International AIDS Society conferences, the Conferences on Retroviruses and Opportunistic Infections, and the International Conference on Cryptococcus and Cryptococcosis were also screened from 2012 to 2017 to identify studies that have been recently completed but not yet published in full. Database searches were supplemented by screening bibliographies of review articles and all included full-text articles. The same investigators scanned all abstracts and full-text articles and achieved consensus on final study inclusions.

Reasons for exclusions included studies using samples other than serum, plasma, or whole blood. If studies included patients with a history of cryptococcal disease or overt clinical meningitis, then these patients were excluded from the study denominators and numerators included in this review; where it was not possible to remove these patients from the study population, the studies were only included if <10% of patients met these criteria. No language or geographical restrictions were applied.

Data Extraction

The same 3 investigators extracted data following a predefined protocol and using a standardized and piloted extraction form. Study characteristics included design, year, population, location, ART status, CrAg positivity by CD4 cell count stratum, and active tuberculosis (TB) infection. Where reported, outcomes for CrAg-positive patients who received or did not receive fluconazole were also extracted. Additional information was extracted to inform an assessment of risk of bias and the certainty of the evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach [14].

Statistical Analysis

To estimate CrAg prevalence by CD4 cell count stratum, point estimates and corresponding 95% confidence intervals (CIs) were calculated and data were pooled using random-effects meta-analysis [15], following data transformation [16, 17]. The same approach was used to summarize clinical outcomes among CrAg-positive patients started and not started on fluconazole. Prevalence odds ratios were calculated to compare diagnostic yield by CD4 cell count strata (≤100 vs 101–200 cells/μL) using random effects models. Heterogeneity was assessed though visual inspection of forest plots and subgroup analyses to examine potential differences by geographical region, clinical setting, type of CrAg screening test used, and sample type. We analyzed all data with Stata version 13.0 software.

RESULTS

Characteristics of Included Studies

From an initial screen of 540 titles, 60 studies were included in this review (Figure 1) [6, 9–12, 18–70]. Among these, 40 were prospective studies (including one randomized trial) and 20 were retrospective studies; 42 studies were published in full, 16 were abstracts, and additional unpublished data were provided from Médecins Sans Frontières (MSF)–supported HIV programs in Kenya and the Democratic Republic of Congo. Data came from 28 countries, with the majority of studies (41) carried out in Africa. Median age of patients ranged from 30 to 47 years, and the proportion who were female ranged from 20% to 74%. Date of study end ranged from 2013–2017 (median 2014). Most studies (41 studies [66%]) used sera as the sample type and a lateral flow assay (34 studies [57%]). Thirty-two studies reported that all patients screened (n = 18 657) were ART naive, while 16 studies (n = 6950) reported that a proportion of patients were ART experienced (median, 41.7% [interquartile range], 18.4%–72.4%) (Supplementary Appendix).

Risk of bias overall was assessed as being moderate (Supplementary Appendix). The majority of studies used a prospective study design (40 studies), were published in full (42 studies), and had <10% missing data (52 studies). Only 2 studies reported blinding of investigators and only 3 studies reported random sampling of patients. In subgroup analysis, none of these risk of bias indicators influenced CrAg prevalence estimates. Overall, the certainty of evidence was rated as moderate.

Prevalence of Cryptococcal Antigenemia

The pooled prevalence of cryptococcal antigenemia as determined by CrAg positivity was 6.5% (95% CI, 5.7%–7.3%; 54 studies) among patients with CD4 count ≤100 cells/μL and 2.0% (95% CI, 1.2%–2.7%; 21 studies) among patients with CD4 count 101–200 cells/μL (Figures 2 and 3).

Twenty-one studies provided sufficient information to compare CrAg prevalence at CD4 count ≤100 cells/μL vs 101–200 cells/μL within each study. The prevalence odds ratio comparing CD4 count ≤100 cells/μL and CD4 count 101–200 cells/μL was 2.5 (95% CI, 1.9–3.3) (Figure 4). Overall, 18.6% (95% CI, 15.4%–22.2%) of the total CrAg-positive cases identified in this sample of patients with CD4 ≤200 cells/μL (n = 11 823) were among individuals with a CD4 count 101–200 cells/μL.

Among patients with CD4 count ≤100 cells/μL, CrAg positivity ranged from 0.3% (95% CI, 0.3%–2.5%) in Iran to 22.8% (95% CI, 17%–29.2%) in DRC (MSF, unpublished data). In subgroup analysis, there was substantial variability by geographical

Figure 1. Study selection process. Abbreviation: HIV, human immunodeficiency virus.

region, with CrAg prevalence highest in the Africa Region (6.7% [95% CI, 5.7%–7.6%]), the South-East Asia Region (6.9% [95% CI, 4.4%–9.5%]), and the Western Pacific Region (13.3% [95% CI, 7.4%–19.1%]). CrAg prevalence was also higher among inpatients (9.8% [95% CI, 4.0%–15.5%]) than outpatients (6.3% [95% CI, 5.3%–7.4%]). A higher prevalence was also seen in studies that used nonfrozen samples (7.8% [95% CI, 6.5%–9.0%]) rather than stored samples (4.7% [95% CI, 3.8%–5.5%]). CrAg prevalence was similar comparing studies that only enrolled ART-naive patients and those that included both ART-naive and ART-experienced patients (Figure 5).

Clinical Outcomes

Nineteen studies reported outcomes among 353 CrAg-positive, asymptomatic PLHIV who were started on fluconazole prophylaxis [9, 11, 19, 21, 24–27, 31, 38, 42, 52, 54, 55, 60–62, 64, 70], with clinical outcomes from one study [19] reported in a separate report [71]. Median follow-up time was 9 months (interquartile range, 6–12 months). Of these, 34 (9.6%) of patients had died, among whom none were documented to have died of cryptococcal meningitis. Nineteen (5.4%) developed incident cryptococcal disease. Fourteen studies reported outcomes among 118 CrAg-positive, asymptomatic PLHIV who were not started on fluconazole prophylaxis [9, 11, 12, 20, 21, 25–27, 31,

38, 41, 42, 70, 71]. Of these, 22 (18.6%) had died, among whom 2 were documented to have died of cryptococcal meningitis; 3 others developed incident cryptococcal disease.

Thirteen studies reported the prevalence of TB disease among patients who were CrAg positive, using different TB screening approaches [9, 11, 19–22, 26, 28, 33, 41, 46, 57, 72]. Among 234 patients screened CrAg positive, 45 also were diagnosed with TB, giving an overall prevalence of coexistent disease of 19.2% (95% CI, 14.4%–24.9%).

DISCUSSION

Cryptococcal meningitis remains an important cause of morbidity and mortality among people with HIV, despite major improvements in access to HIV testing and treatment services [2]. This is largely explained by an enduring burden of advanced HIV disease, either because people present late for diagnosis and care or, increasingly, because PLHIV interrupt ART for a period during which time their CD4 cell count drops, placing them at risk of major opportunistic infections including cryptococcal meningitis [73].

This review estimated prevalence from available studies, by country and region, and found a high prevalence of CrAg positivity among people with advanced HIV disease that, consistent with expectations, was higher among those with a lower CD4 cell count.

Study	Country	% (95% CI)
Vidal	Brazil	3.48 (1.02, 7.32)
Alemu	Ethiopia	11.54 (6.41, 17.92)
Anuradha	India	3.48 (1.02, 7.32)
Beyene	Ethiopia	22.49 (12.92, 33.82)
Chipungu	Malawi	4.27 (0.63, 10.92)
Ezeanolue	Nigeria	3.62 (2.72, 4.64)
MSF Kenya	Kenya	15.98 (10.53, 22.33)
Jarvis	South Africa	6.87 (4.34, 9.93)
Ndayisenga	Guinea	4.22 (2.41, 6.52)
Frola	Argentina	3.80 (1.12, 7.98)
Kwizera	Uganda	6.62 (4.40, 9.27)
Ganiem	Indonesia	7.21 (5.54, 9.09)
Govender	South Africa	3.17 (2.01, 4.59)
Kadam	India	7.89 (4.64, 11.92)
Kwan	Thailand	11.17 (5.40, 18.69)
McKenney	USA	2.96 (2.24, 3.78)
MSF DRC	DRC	22.80 (17.01, 29.16)
Letang	Tanzania	4.51 (2.90, 6.46)
Liechty	Uganda	5.75 (3.67, 8.28)
Longley	South Africa	4.41 (2.96, 6.13)
Magambo	Tanzania	8.77 (3.45, 16.23)
Mamoojee	Ghana	2.66 (0.39, 6.88)
Mamuye	Ethiopia	16.49 (9.72, 24.62)
Meyer	Kenya	11.55 (8.94, 14.45)
Micol	Cambodia	20.67 (16.16, 25.58)
Oladele	Nigeria	10.47 (4.15, 19.23)
Osazuwa	Nigeria	21.34 (13.21, 30.81)
Oyella	Uganda	18.89 (15.06, 23.04)
Pac	Uganda	6.49 (3.35, 10.58)
Patel	UK	5.38 (2.41, 9.42)
Pongsai	Thailand	13.37 (7.04, 21.32)
Reepalu	Ethiopia	0.84 (0.76, 7.15)
Mfinanga	Tanzania & Zambia	4.67 (3.25, 6.33)
Rugemalila	Tanzania	5.19 (2.01, 9.75)
Sawadogo	Namibia	4.00 (2.48, 5.87)
Smith	Vietnam	4.18 (1.97, 7.17)
Tassie	Uganda	6.17 (2.15, 12.07)
Vallabhaneni,	South Africa	2.09 (1.35, 2.99)
Vu	Vietnam	2.70 (1.76, 3.83)
Makadzange	Zimbabwe	10.13 (8.57, 11.81)
Faini	Tanzania	8.09 (5.56, 11.05)
Morawski	Uganda	7.14 (6.09, 8.27)
Kebede	Ethiopia	8.39 (5.91, 11.26)
Govender (IAS 2016)	South Africa	3.03 (2.87, 3.19)
Guha	India	14.34 (8.85, 20.89)
Chim	Cambodia	8.52 (5.85, 11.63)
Lechiile	Botswana	5.64 (4.57, 6.81)
Temfack	Cameroon	8.79 (4.96, 13.57)
Meya	Uganda	9.44 (8.26, 10.69)
Hajiabdolbaghi	Iran	0.29 (0.26, 2.50)
Katchanov	Germany	1.65 (1.11, 2.31)
Ogouyèmi–Hounto	Cameroon	4.16 (1.60, 7.84)
Mhlanga	South Africa	3.40 (2.56, 4.35)
Rick	Lesotho	11.24 (6.39, 17.24)
Overall		6.48 (5.71, 7.25)

Figure 2. Prevalence of CrAg positivity among patients with CD4 count ≤100 cells/μL. Abbreviations: CI, confidence interval; CrAg, cryptococcal antigen; DRC, Democratic Republic of the Congo; IAS, International AIDS Society; MSF, Médecins Sans Frontières.

These findings support current guidance to screen all individuals presenting for care with a CD4 count ≤100 cells/μL. Prevalence at CD4 count ≤100 cells/μL was highest in the Africa, South-East Asia, and Western Pacific regions. The finding that one fifth of CrAg-positive patients were also found to have TB supports the inclusion of CrAg and TB testing as part of a package to manage advanced HIV disease.

This review further suggests that there may be additional benefit to screening individuals at CD4 cell count up to 200 cells/μL, depending on availability of resources and considering the practical advantage of providing the same package of care to all patients with advanced HIV disease within a public health approach. Almost one-fifth of CrAg-positive cases identified at CD4 count ≤200 cells/μL are identified at CD4 between 101 and 200 cells/μL. Cost-effectiveness analyses have so far focused on the benefit of CrAg screening at CD4 count ≤100 cells/μL, and there is some evidence of benefit down to a prevalence of 0.6% of cryptococcal antigenemia [4]. Further cost-effectiveness research is needed to

assess the value of screening at a higher CD4 cell count threshold of 200 cells/μL, which has already been suggested to be cost saving if carried out in inpatient settings [9].

There is a growing evidence base supporting the clinical benefit and cost effectiveness of CrAg screening in combination with enhanced ART adherence and delivery interventions. A trial conducted in the United Republic of Tanzania and Zambia randomized 1999 ART-naive adults living with HIV with a CD4 count <200 cells/μL to receive enhanced clinic-based care with CrAg screening and preemptive antifungal treatment for those who were CrAg positive; importantly, additional community support including ART delivery and adherence counseling was provided to the intervention group. The trial reported a 28% reduction in mortality (13% vs 18%) among people receiving the intervention compared to standard care [52]. In an unpublished post hoc analysis, a statistically significant mortality reduction was found in both people with a CD4 count <100 cells/

Figure 3. Prevalence of CrAg positivity among patients with CD4 count 100–200 cells/μL. Abbreviations: CI, confidence interval; CrAg, cryptococcal antigen; DRC, Democratic Republic of the Congo; MSF, Médecins Sans Frontières.


Figure 4. CrAg prevalence odds ratio (CD4 count ≤100 cells/μL vs 100–200 cells/μL). Abbreviations: CI, confidence interval; CrAg, cryptococcal antigen; DRC, Democratic Republic of the Congo; MSF, Médecins Sans Frontières.

Covariate	% (95% CI)	Number of studies	Number of patients
Setting			
Inpatient	9.77 (4.00, 15.54)	5	2535
Outpatient	6.32 (5.29, 7.35)	38	19398
Inpatient & outpatient	8.06 (6.12, 9.99)	12	47217
Sample			
Serum	8.02 (6.68, 9.36)	37	14713
Plasma	6.01 (3.30, 8.72)	7	45787
Blood	3.96 (2.46, 5.47)	7	6667
Fresh	7.76 (6.50, 9.02)	41	50197
Stored	4.66 (3.82, 5.51)	15	19039
Region			
AFRO	6.70 (5.70, 7.60)	37	61195
SEARO	6.93 (4.41, 9.50)	8	2613
WPRO	13.28 (7.41, 19.14)	3	1153
AMRO S	3.63 (1.31, 5.95)	2	245
AMRO N	2.96 (2.16, 3.71)	1	1872
EURO	3.10 (0.00, 6.65)	2	1880
EMRO	0.29 (0.00, 1.41)	1	86
ART status			
ART experienced	7.33 (4.77, 9.89)	29	14820
ART naïve	7.53 (6.16, 8.90)	10	4685

Figure 5. Factors associated with CrAg positivity at CD4 count ≤100 cells/µL. Abbreviations: ART, antiretroviral therapy; AFRO, Africa Region; AMRO N, North America Region; AMRO S, South America Region; CI, confidence interval; CrAg, cryptococcal antigen; EMRO, Mediterranean Region; EURO, Europe Region; SEARO, South-East Asia Region; WPRO, Western Pacific Region.

µL (mortality rate ratio, 0.75 [95% CI, .58–.95]) and those with a CD4 cell count of 101–200 cells/µL (mortality rate ratio, 0.56 [95% CI, .32–.97]).

A recent study from South Africa reported the numbers of patients starting ART in 2016 at different CD4 cell count thresholds using data from the national laboratory database [74]. According to this analysis, 128 888 patients (16.8% of the total) started ART at a CD4 count ≤100 cells/µL and 123 164 (16.1%) started at a CD4 count of 101–200 cells/µL. Applying the pooled prevalence estimates from this review, 8249 patients (95% CI, 7347–9280) would theoretically be identified as being CrAg positive at a CD4 screening threshold of 100 cells/µL, and an additional 2463 patients (95% CI, 1478–3325) would be identified if a threshold of CD4 200 cells/µL were applied.

The majority of studies included in this review were carried out in Africa, and the findings of this review are of greatest relevance to settings with a high burden of HIV and cryptococcal meningitis. Nevertheless, cryptococcal disease remains an important cause of illness and death among people with HIV in high-income settings, and the role of CrAg screening and preemptive therapy should be considered in these settings [48].

Strengths of this review include a broad and inclusive search strategy that allowed for the identification of a large number of studies for analysis. Heterogeneity was anticipated, and explored using standard methods that increased confidence in the overall findings. The main limitations to note are the limited reporting of important information which may influence CrAg prevalence, notably ART experience, which was missing for one-fifth of studies included in this review, and the limited reporting of clinical outcomes. Another limitation relates to methodological quality, with a number of studies being carried out retrospectively and only 3 studies reporting random patient sampling. While methodological quality did not appear to importantly influence the prevalence estimates, future studies are encouraged to take steps to improve methodological rigor.

This review highlights several directions for research, including the cost effectiveness of screening at higher CD4 cell counts and the appropriateness and cost effectiveness of screening ART-experienced adults and adolescents with low CD4 counts.

In conclusion, the findings of this review support current recommendations to screen all adults and adolescents who have a CD4 count ≤100 cells/µL for CrAg, whether they are ART naive or experienced, and provide preemptive fluconazole treatment to those testing positive. Consideration should also be given to screening at a higher CD4 count of ≤200 cells/µL in settings where there are sufficient resources to implement such an approach, or where a simplified package of care for advanced disease is required based on a unified CD4 threshold.

Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

References

1. Williamson PR, Jarvis JN, Panackal AA, et al. Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. Nat Rev Neurol **2017**; 13:13–24.
2. Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis **2017**; 17:873–81.
3. French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS **2002**; 16:1031–8.
4. Jarvis JN, Harrison TS, Lawn SD, Meintjes G, Wood R, Cleary S. Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLoS One **2013**; 8:e69288.
5. Meya DB, Manabe YC, Castelnuovo B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis **2010**; 51:448–55.
6. Smith RM, Nguyen TA, Ha HT, et al. Prevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program—Vietnam. PLoS One **2013**; 8:e62213.
7. Kimaro GD, Mfinanga S, Simms V, et al. The costs of providing antiretroviral therapy services to HIV-infected individuals presenting with advanced HIV disease at public health centres in Dar es Salaam, Tanzania: findings from a randomised trial evaluating different health care strategies. PLoS One **2017**; 12:e0171917.
8. World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. **2017**. Available at: http://www.who.int/hiv/pub/toolkits/advanced-HIV-disease-policy/en/.
9. Vidal JE, Toniolo C, Paulino A, et al. Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, Brazil. Trop Med Int Health **2016**; 21:1539–44.
10. Ezeanolue EE, Nwizu C, Greene GS, et al. Brief report: geographical variation in prevalence of cryptococcal antigenemia among HIV-infected, treatment-naive patients in Nigeria: a multicenter cross-sectional study. J Acquir Immune Defic Syndr **2016**; 73:117–21.
11. Letang E, Müller MC, Ntamatungiro AJ, et al. Cryptococcal antigenemia in immunocompromised human immunodeficiency virus patients in rural Tanzania: a preventable cause of early mortality. Open Forum Infect Dis **2015**; 2:ofv046.
12. Ogouyèmi-Hounto A, Zannou D, Ayihounton G, et al. Prevalence and factors associated with cryptococcal antigenemia in HIV-infected patients in Cotonou/Benin [in French]. J Mycol Med **2016**; 26, 391–7.
13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med **2009**; 6:e1000097.
14. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ **2008**; 336:924–6.
15. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res **1993**; 2:121–45.
16. Freeman MF TJ. Transformations related to the angular and the square root. Ann Math Stat **1950**; 21: 607–11.
17. Miller J. The inverse of the Freeman-Tukey double arcsine transformation. Am Stat **1978**; 32: 138.
18. Ake J, Maswai J, Kiweewa F, et al. Infectious and noninfectious multimorbidity among HIV clinic clients in the African Cohort Study [abstract 764]. Conference on Retroviruses and Opportunistic Infections, Seattle, 23-26 February **2015**.
19. Alemu AS, Kempker RR, Tenna A, et al. High prevalence of cryptococcal antigenemia among HIV-infected patients receiving antiretroviral therapy in Ethiopia. PLoS One **2013**; 8:e58377.
20. Andama AO, den Boon S, Meya D, et al. Prevalence and outcomes of cryptococcal antigenemia in HIV-seropositive patients hospitalized for suspected tuberculosis in Uganda. J Acquir Immune Defic Syndr **2013**; 63:189–94.
21. Anuradha S, H AN, Dewan R, Kaur R, Rajeshwari K. Asymptomatic cryptococcal antigenemia in people living with HIV (PLHIV) with severe immunosuppression: is routine CrAg screening indicated in India? J Assoc Physicians India **2017**; 65:14–7.
22. Bedell RA, Anderson ST, van Lettow M, et al. High prevalence of tuberculosis and serious bloodstream infections in ambulatory individuals presenting for antiretroviral therapy in Malawi. PLoS One **2012**; 7:e39347.
23. Beyene T, Woldeamanuel Y, Asrat D, Ayana G, Boulware DR. Comparison of cryptococcal antigenemia between antiretroviral naïve and antiretroviral experienced HIV positive patients at two hospitals in Ethiopia. PLoS One **2013**; 8:e75585.
24. Chim B, Soeung S, Heng V, Sopheak T, Lynen L, van Griensven J. Integrated cryptococcal antigen screening and pre-emptive treatment prior to initiation of antiretroviral treatment in HIV-infected adults in Cambodia. In: Seventh IAS Conference, Kuala Lumpur, Malaysia, **2013**.
25. Chipungu C, Veltman JA, Jansen P, et al. Feasibility and acceptability of cryptococcal antigen screening and prevalence of cryptocococcemia in patients attending a resource-limited HIV/AIDS clinic in Malawi. J Int Assoc Provid AIDS Care **2015**; 14:387–90.
26. Faini D, Kalinjuma A, Neborak J, et al. Maximizing detection and improving outcomes of cryptococcosis in rural Tanzania [abstract 760]. In: Conference on Retroviruses and Opportunistic Infections, 2016.
27. Frola C, Guelfand L, Blugerman G, et al. Prevalence of cryptococcal infection among advanced HIV patients in Argentina using lateral flow immunoassay. PLoS One **2017**; 12:e0178721.
28. Ganiem AR, Indrati AR, Wisaksana R, et al. Asymptomatic cryptococcal antigenemia is associated with mortality among HIV-positive patients in Indonesia. J Int AIDS Soc **2014**; 17:18821.
29. Gonzalez F, Paz P, Valencia F, et al. Use of a rapid test for the diagnosis of cryptococcosis in an HIV positive adult population in the city of Popayán, Colombia. International Conference on Cryptococcus and Cryptococcosis, Foz do Iguacu, Brazil; **2017**.
30. Govender N, Sriruttan C, Greene G, et al. Evaluation of reflex laboratory cryptococcal disease screening, South Africa, **2012–2015** [abstract WEPEB032]. 21st International AIDS Conference, Durban, 18–22 July 2016.
31. Govender NP, Roy M, Mendes JF, Zulu TG, Chiller TM, Karstaedt AS. Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa. HIV Med **2015**; 16:468–76.
32. Guha S, Mukherjee M, Dutta N, et al. Routine cryptococcal antigen screening before ART initiation: a study from an ART center of Eastern India. In: Eighth International AIDS Society Conference, Vancouver, Canada, **2015**.
33. Hajiabdolbaghi M, Kalantari S, Jamshidi-Makiani M, et al. Prevalence of cryptococcal antigen positivity among HIV infected patient with CD4 cell count less than 100 of Imam Khomeini Hospital, Tehran, Iran. Iranian J Microbiol **2017**; 9: 119–21.
34. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis **2009**; 48:856–62.
35. Kadam D, Chandanwale A, Bharadwaj R, et al. High prevalence of cryptococcal antigenaemia amongst asymptomatic advanced HIV patients in Pune, India. Indian J Med Microbiol **2017**; 35:105–8.
36. Katchanov J, Jefferys L, Tominski D, et al. Cryptococcosis in HIV-infected hospitalized patients in Germany: evidence for routine antigen testing. J Infect **2015**; 71:110–6.
37. Kebede H, Seyoum H, Abebe Y, et al. The invisible killer: a pilot project on cryptococcal meningitis screening, diagnosis and management in high volume hospitals

in Ethiopia. In: International AIDS Society Conference, 2016. 21st International AIDS Conference, Durban, 18–22 July **2016**; THPEE486.

38. Kwan CK, Leelawiwat W, Intalapaporn P, et al. Utility of cryptococcal antigen screening and evolution of asymptomatic cryptococcal antigenemia among HIV-infected women starting antiretroviral therapy in Thailand. J Int Assoc Provid AIDS Care **2014**; 13:434–7.

39. Kwizera R, Nguna J, Kiragga A, et al. Performance of cryptococcal antigen lateral flow assay using saliva in Ugandans with CD4 <100. PLoS One **2014**; 9:e103156.

40. Lechiile K, Mitchell H, Mulenga F, et al. Prevalence of advanced HIV disease and cryptococcal infection in Gaborone, Botswana [abstract 740]. In: Conference on Retroviruses and Opportunistic Infections, Seattle, **2017**.

41. Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health **2007**; 12:929–35.

42. Longley N, Jarvis JN, Meintjes G, et al. Cryptococcal antigen screening in patients initiating ART in South Africa: a prospective cohort study. Clin Infect Dis **2016**; 62:581–7.

43. Luzinda K, Buard V, Damiani I, et al. Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: a feasibility study in rural Lesotho [abstract TUPED778]. In: Eighth International AIDS Society Conference, Vancouver, Canada, 2015.

44. Magambo KA, Kalluvya SE, Kapoor SW, et al. Utility of urine and serum lateral flow assays to determine the prevalence and predictors of cryptococcal antigenemia in HIV-positive outpatients beginning antiretroviral therapy in Mwanza, Tanzania. J Int AIDS Soc **2014**; 17:19040.

45. Makadzange AT, Hlupeni A, Boyd K, et al. High prevalence of CNS dissemination with asymptomatic cryptococcal antigenemia [abstract 743]. In: Conference on Retroviruses and Opportunistic Infections, Foz do Iguacu, **2017**.

46. Mamoojee Y, Shakoor S, Gorton RL, et al. Short communication: low seroprevalence of cryptococcal antigenaemia in patients with advanced HIV infection enrolling in an antiretroviral programme in Ghana. Trop Med Int Health **2011**; 16:53–6.

47. Mamuye AT, Bornstein E, Temesgen O, Blumberg HM, Kempker RR. Point-of-care testing for cryptococcal disease among hospitalized human immunodeficiency virus-infected adults in Ethiopia. Am J Trop Med Hyg **2016**; 95:786–92.

48. McKenney J, Bauman S, Neary B, et al. Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986–2012. Clin Infect Dis **2015**; 60:959–65.

49. Mendes R, Negri A, Tsujisaki R, et al. Lateral flow assay in the early diagnosis of cryptococcosis in severely immunosupressed AIDS-patients from the Midwest Region of Brazil. In: International Conference on Cryptococcus and Cryptococcosis, Foz do Iguacu, **2017**.

50. Meya D, Rajasingham R, Nalintya E, Tenforde M, Jarvis JN. Preventing cryptococcosis-shifting the paradigm in the era of highly active antiretroviral therapy. Curr Trop Med Rep **2015**; 2:81–9.

51. Meyer AC, Kendi CK, Penner JA, et al. The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya. Trop Med Int Health **2013**; 18:495–503.

52. Mfinanga S, Chanda D, Kivuyo SL, et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet **2015**; 385:2173–82.

53. Mhlanga M, Sriruttan C, Coetzee L, Glencross D, Govender NP. A cross-sectional laboratory survey to determine the prevalence of cryptococcal antigenaemia in South Africa [abstract 5271]. In: Sixth Federation of Infectious Diseases Societies of Southern Africa (FIDSSA) Congress, KwaZulu Natal, South Africa, **2015**.

54. Micol R, Lortholary O, Sar B, et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr **2007**; 45:555–9.

55. Morawski B, Boulware D, Nalintya E, et al. Pre-ART cryptococcal antigen titer associated with preemptive fluconazole failure [abstract 159]. In: Conference on Retroviruses and Opportunistic Infections, Boston, **2016**.

56. Ndayisenga L, Yuma J-D, TiemTore O, et al. *Mycobacterium tuberculosis* lateral flow urine lipoarabinomannan assay (TBLAM) and cryptococcal antigen lateral flow assay (CrAg LFA) as screening among patients with advanced HIV-disease in Conakry, Guinea [abstract TUPEB0375]. In: International AIDS Society Conference, **2017**.

57. Oladele RO, Akanmu AS, Nwosu AO, Ogunsola FT, Richardson MD, Denning DW. Cryptococcal antigenemia in Nigerian patients with advanced human immunodeficiency virus: influence of antiretroviral therapy adherence. Open Forum Infect Dis **2016**; 3:ofw055.

58. Osazuwa F, Dirisu JO, Okuonghae PE, Ugbebor O. Screening for cryptococcal antigenemia in anti-retroviral naïve AIDS patients in Benin City, Nigeria. Oman Med J **2012**; 27:228–31.

59. Oyella J, Meya D, Bajunirwe F, Kamya MR. Response to comment on "prevalence and factors associated with cryptococcal antigenemia among severely immunosuppressed HIV-infected adults in Uganda". J Int AIDS Soc **2012**; 15:18003.

60. Pac L, Horwitz MM, Namutebi AM, et al. Implementation and operational research: integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia. J Acquir Immune Defic Syndr **2015**; 68:e69–76.

61. Patel S, Shin GY, Wijewardana I, et al. The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a southwest London cohort. J Infect **2013**; 66:75–9.

62. Pongsai P, Atamasirikul K, Sungkanuparph S. The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts. J Infect **2010**; 60:474–7.

63. Reepalu A, Balcha TT, Yitbarek T, Jarso G, Sturegård E, Björkman P. Screening for cryptococcal antigenemia using the lateral flow assay in antiretroviral therapy-naïve HIV-positive adults at an Ethiopian hospital clinic. BMC Res Notes **2015**; 8:702.

64. Rick F, Niyibizi AA, Shroufi A, et al. Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: a feasibility study in rural Lesotho. PLoS One **2017**; 12:e0183656.

65. Rugemalila J, Maro VP, Kapanda G, Ndaro AJ, Jarvis JN. Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay. Trop Med Int Health **2013**; 18:1075–9.

66. Sawadogo S, Makumbi B, Purfield A, et al. Estimated prevalence of *Cryptococcus* antigenemia (CrAg) among HIV-infected adults with advanced immunosuppression in Namibia justifies routine screening and preemptive treatment. PLoS One **2016**; 11:e0161830.

67. Tassie JM, Pepper L, Fogg C, et al. Systematic screening of cryptococcal antigenemia in HIV-positive adults in Uganda. J Acquir Immune Defic Syndr **2003**; 33:411–2.

68. Temfack E, Kouanfack C, Loyse A, et al. Prevalence of latent cryptococcosis among HIV-infected patients in Cameroon: the ANRS 12312 PreCASA study. In: International Conference on Cryptococcus and Cryptococcosis, Foz do Iquacu, **2017**.

69. Vallabhaneni S, Longley N, Smith M, et al. Implementation and operational research: evaluation of a public-sector, provider-initiated cryptococcal antigen screening and treatment program, Western Cape, South Africa. J Acquir Immune Defic Syndr **2016**; 72:e37–42.

70. Vu D, Nguyen K, Nguyen D, et al. Cryptoccal antigen screening among patients with advanced HIV infection in Vietnam [abstract 741]. In: Conference on Retroviruses and Opportunistic Infections, Boston, **2016**.

71. Smitson CC, Tenna A, Tsegaye M, et al. No association of cryptococcal antigenemia with poor outcomes among antiretroviral therapy-experienced HIV-infected patients in Addis Ababa, Ethiopia. PLoS One **2014**; 9:e85698.

72. Manabe YC, Nonyane BA, Nakiyingi L, et al. Point-of-care lateral flow assays for tuberculosis and cryptococcal antigenuria predict death in HIV infected adults in Uganda. PLoS One **2014**; 9:e101459.

73. Osler M, Hilderbrand K, Goemaere E, et al. Community CD4 count as a proxy for ongoing morbidity and mortality risk over 10 years of increasing antiretroviral therapy coverage in South Africa. Clin Infect Dis **2018**; 66:S118–25.

74. Carmona S, Bor J, Nattey C, et al. Persistent high burden of advanced human immunodeficiency virus (HIV) disease among patients seeking care in South Africa's national HIV program: data from a nationwide laboratory cohort. Clin Infect Dis **2018**; 66:S111–7.